华恒生物，筹划H股上市

Group 1 - Company Huaheng Biological announced plans to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries [1] - The H-share listing will not result in changes to the company's controlling shareholder or actual controller [1] - The company stated that further arrangements and progress will be based on official announcements [1] Group 2 - Huaheng Biological is a national high-tech enterprise focused on synthetic biology technology, primarily engaged in the R&D, production, and sales of bio-based products [3] - The company's main products include amino acids, vitamins, bio-based new material monomers, and other products, applicable in various fields such as intermediates, animal nutrition, personal care, functional foods, and plant nutrition [3] - In 2024, the company reported a revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, while the net profit attributable to shareholders was 190 million yuan, a year-on-year decrease of 57.8% [3] - The decline in net profit was attributed to increased operational costs due to business expansion and intensified market competition, leading to lower prices for valine products [3] - In the first quarter of 2025, the company achieved a revenue of 687 million yuan, a year-on-year growth of 37.2%, but the net profit attributable to shareholders decreased by 40.98% [3]